Fluvastatin in the Therapy of Acute Coronary Syndrome

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the safety and efficacy of fluvastatin versus placebo, dosed shortly after or immediately when the coronary event occurs.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Collaborator: Ministry of Health, Czech Republic
• Treatments: Fluvastatin

Criteria

Inclusion Criteria:

• Acute coronary syndrome

• Adults, 18 years and older

Exclusion Criteria:

• History of lipid lowering therapy less than 30 days before index event

• Pregnancy and nursing

• Subject younger than 18 years

Other inclusion and exclusion criteria may apply.